Frequent methylation of RASSF1A in synovial sarcoma and the anti-tumor effects of 5-aza-2′-deoxycytidine against synovial sarcoma cell lines

Kunihiko Numoto, Aki Yoshida, Shinsuke Sugihara, Toshiyuki Kunisada, Yuki Morimoto, Yasushi Yoneda, Yasuko Fujita, Keiichiro Nishida, Mamoru Oouchida, Toshihumi Ozaki

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: In this study, the methylation status of RASSF1A in synovial sarcomas and the effect of de-methylation on synovial sarcoma were examined. Methods: The methylation status in 74 soft tissue sarcomas (STSs) including 21 synovial sarcomas was determined by methylation specific PCR. The effect of the de-methylating agent 5-aza-2′-deoxycytidine (5-Aza-dC) on synovial sarcoma was examined using synovial sarcoma cell lines (SYO-1 and HS-SY-II). Results: RASSF1A methylation was observed in 10 (47.6%) of 21 synovial sarcomas and in 10 (18.9%) of 53 the other STSs (P = 0.0295). De-methylation of the cells by treatment with 5-Aza-dC induced re-expression of RASSF1A and growth suppression of the cells. The calculated IC50 of 5-Aza-dC against the SYO-1 and the HS-SY-II cells were 0.9 and 1.3 μM (96 h), respectively. With twice weekly administration of 1 or 10 mg/kg 5-Aza-dC, the growth of the mouse xenograft tumors of SYO-1 was significantly suppressed in comparison to the controls (P <0.01). Conclusion: This is the first report showing the anti-tumor effect of 5-Aza-dC on synovial sarcoma. 5-Aza-dC is suggested to have a good therapeutic potential against synovial sarcoma.

Original languageEnglish
Pages (from-to)17-25
Number of pages9
JournalJournal of Cancer Research and Clinical Oncology
Volume136
Issue number1
DOIs
Publication statusPublished - Jan 2010

Fingerprint

decitabine
Synovial Sarcoma
Methylation
Cell Line
Neoplasms
Sarcoma
Growth
Heterografts
Inhibitory Concentration 50

Keywords

  • 5-aza-2′-deoxycytidine
  • DNA methylation
  • RASSF1A
  • Soft tissue sarcoma
  • Synovial sarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Frequent methylation of RASSF1A in synovial sarcoma and the anti-tumor effects of 5-aza-2′-deoxycytidine against synovial sarcoma cell lines. / Numoto, Kunihiko; Yoshida, Aki; Sugihara, Shinsuke; Kunisada, Toshiyuki; Morimoto, Yuki; Yoneda, Yasushi; Fujita, Yasuko; Nishida, Keiichiro; Oouchida, Mamoru; Ozaki, Toshihumi.

In: Journal of Cancer Research and Clinical Oncology, Vol. 136, No. 1, 01.2010, p. 17-25.

Research output: Contribution to journalArticle

@article{17f6a5a9faf145cbad306d50bf9ff784,
title = "Frequent methylation of RASSF1A in synovial sarcoma and the anti-tumor effects of 5-aza-2′-deoxycytidine against synovial sarcoma cell lines",
abstract = "Purpose: In this study, the methylation status of RASSF1A in synovial sarcomas and the effect of de-methylation on synovial sarcoma were examined. Methods: The methylation status in 74 soft tissue sarcomas (STSs) including 21 synovial sarcomas was determined by methylation specific PCR. The effect of the de-methylating agent 5-aza-2′-deoxycytidine (5-Aza-dC) on synovial sarcoma was examined using synovial sarcoma cell lines (SYO-1 and HS-SY-II). Results: RASSF1A methylation was observed in 10 (47.6{\%}) of 21 synovial sarcomas and in 10 (18.9{\%}) of 53 the other STSs (P = 0.0295). De-methylation of the cells by treatment with 5-Aza-dC induced re-expression of RASSF1A and growth suppression of the cells. The calculated IC50 of 5-Aza-dC against the SYO-1 and the HS-SY-II cells were 0.9 and 1.3 μM (96 h), respectively. With twice weekly administration of 1 or 10 mg/kg 5-Aza-dC, the growth of the mouse xenograft tumors of SYO-1 was significantly suppressed in comparison to the controls (P <0.01). Conclusion: This is the first report showing the anti-tumor effect of 5-Aza-dC on synovial sarcoma. 5-Aza-dC is suggested to have a good therapeutic potential against synovial sarcoma.",
keywords = "5-aza-2′-deoxycytidine, DNA methylation, RASSF1A, Soft tissue sarcoma, Synovial sarcoma",
author = "Kunihiko Numoto and Aki Yoshida and Shinsuke Sugihara and Toshiyuki Kunisada and Yuki Morimoto and Yasushi Yoneda and Yasuko Fujita and Keiichiro Nishida and Mamoru Oouchida and Toshihumi Ozaki",
year = "2010",
month = "1",
doi = "10.1007/s00432-009-0632-2",
language = "English",
volume = "136",
pages = "17--25",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Frequent methylation of RASSF1A in synovial sarcoma and the anti-tumor effects of 5-aza-2′-deoxycytidine against synovial sarcoma cell lines

AU - Numoto, Kunihiko

AU - Yoshida, Aki

AU - Sugihara, Shinsuke

AU - Kunisada, Toshiyuki

AU - Morimoto, Yuki

AU - Yoneda, Yasushi

AU - Fujita, Yasuko

AU - Nishida, Keiichiro

AU - Oouchida, Mamoru

AU - Ozaki, Toshihumi

PY - 2010/1

Y1 - 2010/1

N2 - Purpose: In this study, the methylation status of RASSF1A in synovial sarcomas and the effect of de-methylation on synovial sarcoma were examined. Methods: The methylation status in 74 soft tissue sarcomas (STSs) including 21 synovial sarcomas was determined by methylation specific PCR. The effect of the de-methylating agent 5-aza-2′-deoxycytidine (5-Aza-dC) on synovial sarcoma was examined using synovial sarcoma cell lines (SYO-1 and HS-SY-II). Results: RASSF1A methylation was observed in 10 (47.6%) of 21 synovial sarcomas and in 10 (18.9%) of 53 the other STSs (P = 0.0295). De-methylation of the cells by treatment with 5-Aza-dC induced re-expression of RASSF1A and growth suppression of the cells. The calculated IC50 of 5-Aza-dC against the SYO-1 and the HS-SY-II cells were 0.9 and 1.3 μM (96 h), respectively. With twice weekly administration of 1 or 10 mg/kg 5-Aza-dC, the growth of the mouse xenograft tumors of SYO-1 was significantly suppressed in comparison to the controls (P <0.01). Conclusion: This is the first report showing the anti-tumor effect of 5-Aza-dC on synovial sarcoma. 5-Aza-dC is suggested to have a good therapeutic potential against synovial sarcoma.

AB - Purpose: In this study, the methylation status of RASSF1A in synovial sarcomas and the effect of de-methylation on synovial sarcoma were examined. Methods: The methylation status in 74 soft tissue sarcomas (STSs) including 21 synovial sarcomas was determined by methylation specific PCR. The effect of the de-methylating agent 5-aza-2′-deoxycytidine (5-Aza-dC) on synovial sarcoma was examined using synovial sarcoma cell lines (SYO-1 and HS-SY-II). Results: RASSF1A methylation was observed in 10 (47.6%) of 21 synovial sarcomas and in 10 (18.9%) of 53 the other STSs (P = 0.0295). De-methylation of the cells by treatment with 5-Aza-dC induced re-expression of RASSF1A and growth suppression of the cells. The calculated IC50 of 5-Aza-dC against the SYO-1 and the HS-SY-II cells were 0.9 and 1.3 μM (96 h), respectively. With twice weekly administration of 1 or 10 mg/kg 5-Aza-dC, the growth of the mouse xenograft tumors of SYO-1 was significantly suppressed in comparison to the controls (P <0.01). Conclusion: This is the first report showing the anti-tumor effect of 5-Aza-dC on synovial sarcoma. 5-Aza-dC is suggested to have a good therapeutic potential against synovial sarcoma.

KW - 5-aza-2′-deoxycytidine

KW - DNA methylation

KW - RASSF1A

KW - Soft tissue sarcoma

KW - Synovial sarcoma

UR - http://www.scopus.com/inward/record.url?scp=71449101475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71449101475&partnerID=8YFLogxK

U2 - 10.1007/s00432-009-0632-2

DO - 10.1007/s00432-009-0632-2

M3 - Article

C2 - 19578875

AN - SCOPUS:71449101475

VL - 136

SP - 17

EP - 25

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 1

ER -